U.S. Industrial REITs Stock News

Boeing (BA) is back in focus after recent trading activity, with the share price closing at $244.55 and short term performance data providing investors with additional context on how the stock has moved over the past year. See our latest analysis for Boeing. Recent trading has been strong, with a 1-month share price return of 19.65% and a 1-year total shareholder return of 46.42%. This suggests momentum has been building as investors reassess Boeing’s prospects and risk profile. If Boeing’s...

Wondering if Home Depot at around US$379.74 is offering good value today, or if the price already reflects what you might expect from the business. The share price has recently moved, with returns of 8.7% over the last 7 days, 5.6% over 30 days, 9.8% year to date, 25.1% over 3 years, and 57.0% over 5 years, while the 1 year return sits at a 0.9% decline. Recent coverage has focused on Home Depot as a major US home improvement retailer, with investors watching how consumer spending on housing...

CRISPR Therapeutics (CRSP) recently outlined a packed 2026 roadmap, highlighting global CASGEVY commercialization, fresh regulatory submissions, and multiple readouts and trial starts across its in vivo and CAR T gene editing programs. See our latest analysis for CRISPR Therapeutics. The recent roadmap update and upcoming J.P. Morgan Healthcare Conference appearance come after a mixed year for the stock. The 1-year total shareholder return of 46.45% contrasts with a 21.78% decline in the 3...

If you are wondering whether DexCom's current share price lines up with its underlying worth, this article will walk through what the numbers are really saying about the stock. DexCom recently closed at US$70.25, with returns of 0.5% over 7 days, 4.9% over 30 days and 5.6% year to date, while the 1 year and 3 year returns sit at an 11.3% and 35.9% decline and the 5 year return at a 21.4% decline. Recent coverage around DexCom has focused on its position in glucose monitoring and how...

Beam Therapeutics (BEAM) has attracted investor attention after recent share price moves, with the stock closing at US$34.55 and showing double digit returns over the past month and over the past three months. See our latest analysis for Beam Therapeutics. Looking beyond the recent surge, Beam Therapeutics’ 1 month share price return of 26.28% and year to date share price return of 27.30% sit alongside a 1 year total shareholder return of 48.28%. This suggests momentum has recently been...

General Mills (GIS) is back in focus after second quarter results came in ahead of expectations on sales and profit, even as the company faces falling unit volumes and higher capital needs. See our latest analysis for General Mills. At a share price of $44.27, General Mills has seen a 1-day share price return of 1.82% but a 1-year total shareholder return decline of 20.92%. This suggests that recent momentum is still weak despite the earnings beat and comments about “improved momentum” in a...

Earlier this week, Labcorp expanded its molecular residual disease (MRD) portfolio, adding Plasma Detect ID for stage I–III breast and stage I–IIIA non-small cell lung cancer and making Plasma Detect Genome MRD testing for stage III colon cancer available nationwide, enabling highly sensitive detection of circulating tumor DNA after treatment. This push deeper into MRD testing reinforces Labcorp’s role in precision oncology, with ultra–low limit-of-detection ctDNA assays that aim to inform...

Enphase Energy has already begun U.S. production shipments of its IQ9N-3P Commercial Microinverter, a gallium nitride–based, three-phase 480Y/277 V device built domestically to meet content and FEOC compliance requirements for commercial solar projects. The launch extends Enphase’s panel-level microinverter architecture into the 480 V commercial market, aiming to simplify system design, trim installation costs, and enhance per-panel monitoring and safety for complex rooftop...

Bloom Energy (BE) is back in the spotlight after a fresh $2.65b expansion of its American Electric Power partnership for solid oxide fuel cells tied to AI hungry data centers. See our latest analysis for Bloom Energy. The latest American Electric Power deal comes after several AI focused data center wins, a multi billion dollar arrangement with Brookfield Asset Management, and a new US$600m credit facility that increased Bloom Energy’s financial flexibility. Against that backdrop, the share...

Edgewise Therapeutics (EWTX) shares were in focus after the company outlined a packed 2026 clinical calendar, detailing timelines for pivotal trials, planned regulatory filings, and key readouts across its muscle and cardiovascular programs. See our latest analysis for Edgewise Therapeutics. The recent clinical roadmap has coincided with strong momentum in the share price, with a 59.73% 90 day share price return but a 9.34% decline in 1 year total shareholder return. The 3 year total...

American Airlines recently partnered with award-winning Pecan Lodge to offer Texas-style barbecue on select Dallas–Fort Worth to New York routes and received multiple analyst upgrades citing fleet renewal and premium product focus. Together, these moves highlight how American is leaning on differentiated customer experience and analysts’ improving views of its business direction to influence investor sentiment. We'll now explore how American’s premium-focused initiatives, such as the Pecan...

If you are wondering whether CareDx at around US$20.19 is starting to look interesting again, you are not alone. This article is here to help you think through the value question. The share price has seen a 7.3% gain over the last week, while the 30 day return sits at a 1.8% decline and the 1 year return is a 8.4% decline. This is against a 42.3% gain over 3 years and a 78.4% decline over 5 years. Recent news coverage of CareDx has focused on how investors are reassessing the company in...

Tradeweb Markets Inc. reported past record total trading volume of $63.0 trillion for December 2025 and $185.3 trillion for the fourth quarter, with average daily volume for both periods rising very large year over year and preliminary fee metrics highlighting the scale of its electronic trading activity. The combination of surging volumes and disclosed preliminary variable and fixed fees offers a clearer view of how Tradeweb is converting higher activity into revenue. Next, we will examine...

Biogen recently received European Commission marketing authorization for a high-dose SPINRAZA regimen to treat 5q spinal muscular atrophy, covering rapid-loading 50 mg doses followed by 28 mg maintenance injections every four months. This decision, grounded in the DEVOTE Phase 2/3 trial showing statistically significant motor function gains with a safety profile consistent with nusinersen, meaningfully broadens treatment options for the vast majority of SMA patients in Europe. We’ll now...

Alumis (ALMS) is back in focus after reporting positive Phase 3 ONWARD1 and ONWARD2 results for its TYK2 inhibitor envudeucitinib in plaque psoriasis, followed by a completed US$300.05 million follow-on equity offering. See our latest analysis for Alumis. The upbeat Phase 3 data and follow on equity offering have coincided with strong near term momentum, with a 30 day share price return of 92.43% and a year to date share price return of 146.90%, while the 1 year total shareholder return of...

If you are wondering whether Coeur Mining's recent share price puts it at an attractive entry point, the next sections will walk through what the current valuation might be telling you. The stock last closed at US$20.96, with reported returns of 6.8% over 7 days, 21.5% over 30 days, 19.4% year to date and 230.1% over the past year. This naturally raises questions about both opportunity and risk at today’s price. Investors have been reacting to company specific developments and broader moves...

UBS’ decision to downgrade Perimeter Solutions (PRM) from Buy to Neutral, while the company funds its Medical Manufacturing Technologies acquisition through a $550 million note offering, has put the stock’s risk and return trade off in sharper focus. See our latest analysis for Perimeter Solutions. At a share price of $28.08, Perimeter Solutions has seen a 24.58% 3 month share price return and a 116.33% 1 year total shareholder return. This suggests recent momentum remains positive even as...

Western Digital’s recent spin-off of its flash business and sharpened focus on hard disk drives for data centers have intersected with bullish trading signals, including repeated tests of a key technical resistance level and strong order-flow “Power Inflow” alerts earlier this month. This combination of a more specialized business model and concentrated buying activity highlights how AI-driven data center demand and hyperscaler spending are increasingly central to Western Digital’s current...

If you are wondering whether Zai Lab's current share price lines up with its underlying worth, this article walks through the numbers so you can form your own view. Zai Lab's stock closed at US$18.72, with returns of 2.9% over the last 7 days, 5.3% over the last 30 days and 8.0% year to date, while the 1 year, 3 year and 5 year returns stand at a 22.9% decline, 58.5% decline and 89.9% decline respectively. Recent share price moves sit against an ongoing flow of company updates and sector...

Wealthfront (WLTH) just posted its Q3 2026 numbers, with revenue of US$93.2 million, basic EPS of US$0.72 and trailing twelve month EPS of US$3.04 setting the backdrop for the quarter. The company has seen revenue move from US$80.3 million in Q3 2025 to US$93.2 million in Q3 2026, while quarterly EPS has shifted from US$0.77 to US$0.72 over the same period, against trailing twelve month revenue of US$351.5 million. With a current net profit margin of 35.2% versus 57.7% a year ago, this update...

Morgan Stanley recently initiated coverage on GRAIL (GRAL.US) with a hold rating, as analyst Kallum Titchmarsh issued his first formal view on the company. This new coverage introduces an additional institutional lens on GRAIL’s multi-cancer early detection business, potentially shaping how investors interpret its risk‑reward profile. We'll now examine how Morgan Stanley's new hold rating interacts with expectations for Galleri adoption, profitability paths, and long-term earnings...

If you are wondering whether Intercontinental Exchange at around US$166 per share offers reasonable value today, the key is understanding how its current price lines up with different valuation yardsticks. The stock has recently posted returns of 0.4% over 7 days, 2.1% over 30 days, 4.2% year to date, 16.1% over 1 year, 61.3% over 3 years, and 54.7% over 5 years, which gives useful context for how the market has been pricing its prospects and risks. Recent coverage around Intercontinental...

Wondering if Celsius Holdings is still reasonably priced after its strong run, or if the value case is already played out? This article is built to help you size that up with clear valuation checks. The stock last closed at US$52.61, with returns of 8.1% over 7 days, 20.0% over 30 days, 10.2% year to date and 95.8% over 1 year, which naturally raises questions about how much future upside or risk is already reflected in the price. Recent attention on Celsius has centered on its position in...

Eos Energy Enterprises recently hosted its “Eos in Focus” event on January 14, where management reviewed full-year 2025 financial and operating results and outlined its business outlook for 2026. This update is important because it gives investors fresh detail on how Eos’s scale-up and technology roadmap are progressing against its long-term plans. We’ll now examine how the fresh operational and 2026 outlook detail from “Eos in Focus” could influence Eos’s investment narrative. The latest...